Skip to main content
Premium Trial:

Request an Annual Quote

Abbott to Distribute More Diagnostic Tests from Artus

NEW YORK, April 15 (GenomeWeb News) - Abbott Laboratories will distribute additional molecular diagnostic tests from Artus, the companies said yesterday.

 

Under the expanded agreement, Abbott will offer all real-time-PCR-based diagnostic tests developed by Artus of Hamburg, Germany, that run on Applied Biosystems instruments. These include tests for hepatitis B virus, Epstein Barr virus, Varicella Zoster virus, Parvo B19 virus, cytomegalovirus, herpes simplex virus, and enterovirus.

 

Abbott already distributes Artus' tests for SARS, Chlamydia trachomatis, and Mycobacterium tuberculosis, as well as other assays on the ABI platform. Abbott markets these test through an exclusive alliance with Celera Diagnostics.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.